17 episodes

Highlights from ecancer's coverage of the 2014 ASCO Annual Meeting. For more interviews, press conference and news visit ecancer's conference page.

http://ecancer.org/conference/514-asco-2014.php

2014 ASCO Annual Meeting ecancer

    • Medicine
    • 1.0 • 1 Rating

Highlights from ecancer's coverage of the 2014 ASCO Annual Meeting. For more interviews, press conference and news visit ecancer's conference page.

http://ecancer.org/conference/514-asco-2014.php

    • video
    ASCO 2014 roundup

    ASCO 2014 roundup

    ecancer's Prof McVie provides a roundup of the main points of discussion from ASCO 2014.

    • 12 min
    • video
    Comment: CALGB/SWOG 80405 study on chemo combos in colorectal

    Comment: CALGB/SWOG 80405 study on chemo combos in colorectal

    Prof Peeters talks to ecancertv at ASCO 2014 about the results of the results from a large federally funded phase III study demonstrate that four common first-line treatment regimens – bevacizumab plus chemotherapy and cetuximab plus chemotherapy – are equally effective for patients with metastatic colorectal cancer and no KRAS mutations.

    • 2 min
    • video
    Adding lapatinib to adjuvant trastuzumab does not improve outcomes in early- stage HER2-positive breast cancer

    Adding lapatinib to adjuvant trastuzumab does not improve outcomes in early- stage HER2-positive breast cancer

    Dr Perez talks to ecancertv at ASCO 2014 about the findings from a large phase III study, ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) which suggest that post-surgery (adjuvant) treatment using a combination of two HER2-targeted drugs – trastuzumab and lapatinib – is no more effective than standard treatment with trastuzumab alone for women with early HER2-positive breast cancer.

    • 5 min
    • video
    Inhibition of PD-L1 using drug MPDL3280A for patients with metastatic urothelial bladder cancer

    Inhibition of PD-L1 using drug MPDL3280A for patients with metastatic urothelial bladder cancer

    Prof Thomas Powles (Barts Health, London, UK) discusses the use of the drug MPDL3280A to inhibit the protein PD-L1 in patients with metatastatic urothelial bladder cancer.

    • 5 min
    • video
    Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL

    Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL

    Dr Byrd talks to ecancertv at ASCO 2014 about the early findings from the phase III RESONATE study which indicate that ibrutinib yields lasting tumour responses and marked improvement in survival over standard of atumumab for patients with relapsed chronic lymphocytic leukaemia (CLL).

    • 4 min
    • video
    HPV-targeted adoptive T Cell therapy for advanced cervical cancer

    HPV-targeted adoptive T Cell therapy for advanced cervical cancer

    Dr Hinrichs talks to ecancertv at ASCO 2014 about his work using immunotherapy to tackle cervical cancer. HPV-targeted tumour-infiltrating lymphocytes for the treatment of cervical cancer is a new field.

    • 5 min

Customer Reviews

1.0 out of 5
1 Rating

1 Rating

Top Podcasts In Medicine

Listeners Also Subscribed To

More by ecancer